Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTH1R | Q03431 | 10/20 | 0.62 |
| ▸ | GLP1R | P43220 | 2/20 | 0.59 |
| ▸ | CCKBR | P32239 | 1/20 | 0.59 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.57 |
| ▸ | VIPR2 | P41587 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neurokinin A SCHEMBL29374005 | 1.00 | PTH1R (0.62) | PTH1RGLP1RCCKBRVIPR1NR3C1 | |
| Neurokinin A SCHEMBL29357512 | 0.90 | CALCR (0.57) | PTH1RGLP1R | |
| Neurokinin B SCHEMBL29440672 | 0.88 | GRPR (0.59) | — | |
| Neurokinin B SCHEMBL29390479 | 0.88 | GRPR (0.59) | — | |
| SCHEMBL19493087 | 0.87 | NR3C1 (0.61) | PTH1RGLP1RCCKBRVIPR1NR3C1 | |
| SCHEMBL31104935 | 0.85 | GLP1R (0.70) | PTH1RGLP1RCCKBRVIPR1NR3C1 | |
| SCHEMBL29678561 | 0.85 | CCKAR (0.51) | PTH1RCCKBR | |
| SCHEMBL2189862 | 0.84 | OPRM1 (0.55) | — | |
| SCHEMBL29509767 | 0.84 | PTH1R (0.68) | PTH1RGLP1RCCKBRVIPR1 | |
| Tyrlysseraspserphetyrglyleumet SCHEMBL30475005 | 0.83 | OPRM1 (0.61) | CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4110768-A1 | CHELATOR COMPOSITIONS FOR RADIOMETALS AND METHODS OF USING SAME | Triumf Inc. (CA) | 2023-01-04 | — | — | EP | claimed |
| US-20260137691-A1 | WB3 FOR ANESTHESIA AND TREATING PAIN | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2026-05-21 | — | — | US | disclosed |
| US-12240816-B2 | Deuterated compounds and uses thereof | ALDEYRA THERAPEUTICS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20250041440-A1 | COMPOSITIONS AND METHODS FOR PREVENTION OR REDUCTION OF CARPA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-02-06 | — | — | US | disclosed |
| EP-4444337-A1 | COMPOSITIONS AND METHODS FOR PREVENTION OR REDUCTION OF CARPA | The Trustees of The University of Pennsylvania (US) | 2024-10-16 | — | — | EP | disclosed |
| EP-4438720-A2 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | Janssen Biotech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | OD THERAPEUTICS LIMITED (CN) | 2024-08-15 | — | — | US | disclosed |
| US-20240269228-A1 | SELECTIVE PENICILLAMINE SUBSTITUTION ENABLES DEVELOPMENT OF A POTENT ANALGESIC PEPTIDE THAT ACTS THROUGH A NON-OPIOID BASED MECHANISM | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2024-08-15 | — | — | US | disclosed |
| EP-3527658-B1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | JANSSEN BIOTECH INC (US) | 2024-07-24 | — | — | EP | disclosed |
| US-20240199618-A1 | NOVEL N-ACYL-[3-SUBSTITUTED]-[8-SUBSTITUTED]-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | OGEDA SA (BE) | 2024-06-20 | — | — | US | disclosed |
| EP-4046995-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | Sunovion Pharmaceuticals Inc. (US) | 2022-08-24 | — | — | EP | disclosed |
| EP-4037715-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | Beijing Xuanyi Pharmasciences Co., Ltd. (CN) | 2022-08-10 | — | — | EP | disclosed |
| EP-3256466-B9 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2022-07-27 | — | — | EP | disclosed |
| US-20220185799-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2022-06-16 | — | — | US | disclosed |
| US-11352391-B2 | Compositions for inducing urinary voiding and defecation | DIGNIFY THERAPEUTICS, LLC (US) | 2022-06-07 | — | — | US | disclosed |
| CN-114599382-A | Agonists of Tacr2 | 哥本哈根大学 | 2022-06-07 | — | — | CN | disclosed |
| EP-3256466-B1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-11285216-B2 | Animal protein-free pharmaceutical compositions | ALLERGAN, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| EP-3957716-A1 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | Janssen Biotech, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20220031846-A1 | ANIMAL PROTEIN-FREE PHARMACEUTICAL COMPOSITIONS | ALLERGAN, INC. | 2022-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199618-A1 | NOVEL N-ACYL-[3-SUBSTITUTED]-[8-SUBSTITUTED]-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-a]PYRAZINES AS SELECTIVE NK-3 RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITION, METHODS FOR USE IN NK-3 RECEPTOR-MEDIATED DISORDERS | PKD1, FFAR3, GPR3 | PTH1R 3235/4885GLP1R 650/4885CCKBR 1125/4885 |
| US-20240269293-A1 | PROTEIN-MACROMOLECULE CONJUGATES AND METHODS OF USE THEREOF | CD44, MACROD1, MSN | PTH1R 3840/4885GLP1R 3793/4885CCKBR 4256/4885 |
| US-20260137691-A1 | WB3 FOR ANESTHESIA AND TREATING PAIN | WNT3, TRPV3, ADRB3 | PTH1R 1547/4885GLP1R 3066/4885CCKBR 1981/4885 |
| US-20220185799-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | CNR1, HCRTR1, CNR2 | PTH1R 4349/4885GLP1R 3109/4885CCKBR 425/4885 |
| US-12240816-B2 | Deuterated compounds and uses thereof | ALDH1A2, SSB, DBH | PTH1R 3498/4885GLP1R 3683/4885CCKBR 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.